

42 7315

Health checkup at tie-up Ctr

HealthChkup Authorisatn letter



Union Bank of India

RO - CHANDIGARH
64/65, BANK SQUARE, SECTOR 17-B,
Chandigarh, Pin - 160 017., Chandigarh-172

To,

The Chief Medical Officer

M/S Mediwheel
https://mediwheel.in/signup011-41195959(A brand name of Arcofemi Healthcare Ltd),
Mumbai400021

Dear Sir,

Tie-up arrangement for Health Checkup under Health Checkup

Executive Male 35+

Shri/Smt./Kum. .,PINTU

P.F. No. 533475

Designation : CHIEF MANAGER

Checkup for Financial Year

2023-2024

Approved Charges Rs.

4000.00

The above mentioned staff member of our Branch/Office desires to undergo Health Checkup(for Executives) at your Hospital/Centre/Clinic, under the tie-up arrangement entered into with you, by our bank.

Please send the receipt of the above payment and the relevant reports to our above address.

Thanking you,

Yours Faithfully,

(Signature of the Employee)


BRANCH MANAGER/SENIOR MANAGER

PS. : Status of the application- **Sanctioned**

View Worklist









Ivy Hospital

SUPER-SPECIALITY HEALTHCARE
SECTOR 71, MOHALI
Tel: 0172-7170000
CIN No.: UBS110PB2005#TC027898

Name: PINTU YADAV UHID: 427375
 Age: _____ Consultant: Dr. Mitesh Vats Date: 9/3/24
 BP: _____ Pulse: _____ RR: _____ Temp: _____ Pain: _____
 Ht: _____ Wt: _____ Allergies: _____ Nutritional Assessment: Yes/No
 Diagnosis / DD: _____
 Complaint: _____

Investigations

nmf ck
ck
(U.A.)


IOH 12/16

Clinical Notes

no general check-up
 on
 ALS - WNL
 C.O.

Pupil - N5NR
 color vision WNL
 WNL

fundus op es



Disc + Macula (N)

| S.No. | Salt/Generic Name | Route | Dose | Frequency | Duration | Special Instructions |
|-------|-------------------|-------|------|-----------|----------|--|
| | | | | | | Adv: (1) Refrains from old TDSOP / Quina Plus old |
| | | | | | | R/A comments / SOS |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Follow up

Vats
 Mitesh Vats
 Retina Consultant & Phaco Surgeon
 Sign & Stamp



Package

Ivy Hospital

SUPER-SPECIALITY HEALTHCARE
SECTOR 71, MOHALI
Tel: 0172-7170000
CIN No.: U85110PB2005PTC027898

Name: Mr. Pintu Yadav UHID: 427375
 Age: 35yrs Consultant: Dr. G. Ranjeeth Kumar Date: 9-3-24
 BP: 120/80 Pulse: 82 bpm RR: _____ Temp.: _____ Pain: _____
 Ht.: _____ Wt.: _____ Allergies: _____ Nutritional Assessment: Yes/No
 Diagnosis / DD: _____
 Complaint: _____

Investigations

Clinical Notes

WDR-PA - NA
 TSH - 1.0
 FBS 96 mg/dl
 RFT - 26 / 0-9
 Cholesterol / TG / HDL / LDL
 197 / 214 / 48 / 96
 Amy - 16.4 / 5800 / 225 > 23
 USG abd - 9x6 Hepatomegaly
 Bxrdiom splenomegaly
 LFT - N
 ESR - 5

Regular Annual checkups
Adv
 low fat diet
 Regular exercise
 No Allergic Rhinitis

| S.No. | Salt/Generic Name | Route | Dose | Frequency | Duration | Special Instructions |
|-------|-------------------|-------|------|-----------|----------|----------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Follow up

[Signature]
 Dr. G. Ranjeeth Kumar
 MD Internal Medicine (DIMER)
 Regn. No.: 88598
 Sign & Stamp
 Ivy/OPD/Form/005

IVY HOSPITAL
Sector 71
Mohali, Punjab

Ward
Telephone:

EXERCISE STRESS TEST REPORT

Patient Name: YADAV, PINTU
Patient ID: 427375
Height: 180 cm
Weight: 90 kg

DOB: 05.01.1989
Age: 35yrs
Gender: Male
Race: Indian

Study Date: 09.03.2024
Test Type: Treadmill Stress Test
Protocol: BRUCE

Referring Physician: --
Attending Physician: --
Technician: TANISHA

Medications:

Medical History:

Reason for Exercise Test:
Screening for CAD

Exercise Test Summary

| Phase Name | Stage Name | Time in Stage | Speed (km/h) | Grade (%) | HR (bpm) | BP (mmHg) | Comment |
|------------|------------|---------------|--------------|-----------|----------|-----------|---------|
| PRETEST | SUPINE | 00:12 | 0.00 | 0.00 | 83 | 120/80 | |
| | STANDING | 00:01 | 0.00 | 0.00 | 83 | 120/80 | |
| | WARM-UP | 00:15 | 1.60 | 0.00 | 83 | 120/80 | |
| EXERCISE | STAGE 1 | 03:00 | 2.70 | 10.00 | 108 | 120/80 | |
| | STAGE 2 | 03:00 | 4.00 | 12.00 | 129 | 120/80 | |
| | STAGE 3 | 03:00 | 5.40 | 14.00 | 155 | 130/80 | |
| | STAGE 4 | 01:14 | 5.80 | 16.00 | 176 | 150/80 | |
| RECOVERY | | 03:35 | 0.00 | 0.00 | 109 | 140/80 | |

The patient exercised according to the BRUCE for 10:14 mins, achieving a work level of Max. METS: 11.80. The resting heart rate of 78 bpm rose to a maximal heart rate of 176 bpm. This value represents 95 % of the maximal, age-predicted heart rate. The resting blood pressure of 120/80 mmHg, rose to a maximum blood pressure of 150/80 mmHg. The exercise test was stopped due to Target heart rate achieved.

Interpretation

Summary: Resting ECG: normal. Functional Capacity: normal. HR Response to Exercise: appropriate. BP Response to Exercise: normal resting BP - appropriate response. Chest Pain: none. Arrhythmias: none. ST Changes: none. Overall impression: Normal stress test.

Conclusions

TMT NEGATIVE FOR INDUCIBLE ISCHEMIA.

Physician

9/3/24
Dr. Rakesh Ghutungru
Director-Non Invasive Cardiology
MBBS, MD (Medicine), DM (Cardiology)
PMC - 42588

Technician

GE Healthcare REF: 2104768-001

CE

Tabular Summary

IVY HOSPITAL

YADAV, PINTU
 Patient ID: 427375

103.2024 Male 180 cm 90 kg
 129:40am 35yrs Indian
 Meds:

Test Reason: Screening for CAD

Medical History:

Ref. MD: Ordering MD:
 Technician: TANISHA Test Type: Treadmill Stress Test
 Comment:

BRUCE Total Exercise Time 10:14
 Max HR: 176 bpm 95% of max predicted 185 bpm
 Max BP: 150/80 Maximum Workload: 11.80 METS
Reasons for Termination: Target heart rate achieved
Summary: Resting ECG: normal. Functional Capacity: normal. HR Response to Exercise: appropriate. BP Response to Exercise: normal resting BP - appropriate response. Chest Pain: none. Arrhythmias: none. ST Changes: none. Overall impression: Normal stress test.
Conclusion: TMT NEGATIVE FOR INDUCIBLE ISCHEMIA.
 Location Number: * 0 *

| Phase | Stage Name | Time in Stage | Speed (km/h) | Grade (%) | Workload (METS) | HR (bpm) | BP (mmHg) | RPP (*100) | VE (/min) | Comment |
|----------|------------|---------------|--------------|-----------|-----------------|----------|-----------|------------|-----------|---------|
| RETEST | SUPINE | 00:12 | 0.00 | 0.00 | 1.0 | 83 | 120/80 | 99 | 0 | |
| | STANDING | 00:01 | 0.00 | 0.00 | 1.0 | 83 | 120/80 | 99 | 0 | |
| | WARM-UP | 00:15 | 1.60 | 0.00 | 1.0 | 83 | 120/80 | 99 | 0 | |
| EXERCISE | STAGE 1 | 03:00 | 2.70 | 10.00 | 4.6 | 108 | 120/80 | 129 | 0 | |
| | STAGE 2 | 03:00 | 4.00 | 12.00 | 7.0 | 129 | 120/80 | 154 | 0 | |
| | STAGE 3 | 03:00 | 5.40 | 14.00 | 10.0 | 155 | 130/80 | 201 | 0 | |
| | STAGE 4 | 01:14 | 5.80 | 16.00 | 11.0 | 176 | 150/80 | 264 | 0 | |
| RECOVERY | | 03:35 | 0.00 | 0.00 | 1.0 | 109 | 140/80 | 152 | 0 | |





Selected Medians Report

IVY HOSPITAL

YADAV, PINTU
 Patient ID 427375
 09.03.2024
 10:29:40am

| BASELINE EXERCISE | PEAK EXERCISE EXERCISE | TEST END RECOVERY |
|-------------------|------------------------|-------------------|
| 0:00 | 10:14 | 3:15 |
| 84 bpm | 176 bpm | 108 bpm |
| | 150/80 mmHg | 140/80 mmHg |

| BASELINE EXERCISE | PEAK EXERCISE EXERCISE | TEST END RECOVERY |
|-------------------|------------------------|-------------------|
| 0:00 | 10:14 | 3:15 |
| 84 bpm | 176 bpm | 108 bpm |
| | 150/80 mmHg | 140/80 mmHg |



GE CASE V6.51 (0)
 10mm/mV 60Hz 0.01-20Hz S+

Unconfirmed

Attending MD:

YADAV PINTU
Patient ID: 427375
03.2024
0:43:13am

108 bpm
02:49 140/80 mmHg

RECOVERY
#1
02:50

BRUCE
0.0 km/h
0.0 %

IVY HOSPITAL
Measured at 60ms Post J (10mm-mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 0.85 | V1 | -0.40 |
| II | 1.15 | V2 | 1.80 |
| III | 0.30 | V3 | 2.50 |
| aVR | -1.05 | V4 | 1.90 |
| aVL | 0.30 | V5 | 0.95 |
| aVF | 0.75 | V6 | 0.45 |



YADAV PINTU
Patient ID: 427375
9.03.2024
10:42:13am

125 bpm
00:40 150 80 mmHg

RECOVERY
#1
01:50

BRUCE
0.0 km/h
0.0 %

IVY HOSPITAL
Measured at 60ms Post J (10mm mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.10 | V1 | -0.55 |
| II | 1.85 | V2 | 2.30 |
| III | 0.80 | V3 | 3.60 |
| aVR | -1.45 | V4 | 2.70 |
| aVL | 0.15 | V5 | 1.60 |
| aVF | 1.30 | V6 | 0.85 |



GE
CASE:V6.51 25 mm/s 10 mm/mV 60Hz 0.01 - 20Hz S+ HR(V6,V2)

GE Healthcare

REF:2104768-001

CE

Start of Test: 10:29:40am

YADAV PINTU
Patient ID: 427375
9.03.2024
8:41:13am

142 bpm
00:40 150/80 mmHg

RECOVERY
#1
00:50

BRUCE
0.0 km/h
0.0 %

IVY HOSPITAL
Measured at 60ms Post J (10mm mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.45 | V1 | -1.20 |
| II | 3.15 | V2 | 2.90 |
| III | 1.70 | V3 | 5.10 |
| aVR | -2.30 | V4 | 4.00 |
| aVL | -0.15 | V5 | 2.50 |
| aVF | 2.45 | V6 | 1.50 |



CASE V6.51

25 mm/s 10 mm/mV 60Hz 0.01 - 20Hz S+ HR(V6,V2)
PRINTED IN U.S.A. 3

Start of Test: 10:29:40am

(PEAK EXERCISE)

YADAV PINTU
Patient ID: 427375
9.03.2024
10:40:23am

176 bpm

EXERCISE
STAGE 4
10:14

BRUCE
5.8 km/h
16.0%

IVY HOSPITAL
Measured at 60ms Post J (+10mm mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.25 | V1 | -0.90 |
| II | 1.40 | V2 | 2.25 |
| III | 0.15 | V3 | 3.25 |
| aVR | -1.30 | V4 | 2.50 |
| aVL | 0.55 | V5 | 1.25 |
| aVF | 0.75 | V6 | 0.50 |



YADAV PINTU
Patient ID: 423375
9/03/2024
0:38:59am


153 bpm
00:56:13 @ 80 mmHg

EXERCISE
STAGE: 3
08:50

BRUCE
5.4 km/h
14.0 %

IVY HOSPITAL
Measured at 60ms Post J (10mm mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.15 | V1 | -0.85 |
| II | 1.70 | V2 | 2.15 |
| III | 0.50 | V3 | 3.40 |
| aVR | -1.45 | V4 | 2.60 |
| aVL | 0.35 | V5 | 1.40 |
| aVF | 1.05 | V6 | 0.60 |



4E
CASE V6:51

25 mm/s, 10 mm/mV, 60Hz, 0.01 - 20Hz, S+HR(V5, V6)

Start of Test: 10:29:46am

PRINTED IN U.S.A. 3

YADAV PINTU
Patient ID: 427375
03.2024
08:35:59am


129 bpm
02:48 120/80 mmHg

EXERCISE
STAGE 2
05:50

BRUCE
4.0 km/h
12.0%

IVY HOSPITAL
Measured at 60ms Post J (10mm mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.00 | V1 | -0.75 |
| II | 2.10 | V2 | 1.95 |
| III | 1.05 | V3 | 3.30 |
| aVR | -1.55 | V4 | 2.75 |
| aVL | 0.00 | V5 | 1.55 |
| aVF | 1.55 | V6 | 0.90 |



YADAV PINTU
Patient ID: 427375
9.03.2024
10:32:59am



110 bpm
02:07 120.80 mmHg

EXERCISE
STAGE 1
02:50

BRUCE
2.7 km/h
10.0 %

IVY HOSPITAL
Measured at 60ms Post J (10mm/mV)
Auto Points

| Lead | ST(mm) | Lead | ST(mm) |
|------|--------|------|--------|
| I | 1.15 | V1 | -0.65 |
| II | 2.20 | V2 | 2.00 |
| III | 1.10 | V3 | 3.15 |
| aVR | -1.70 | V4 | 2.65 |
| aVL | 0.00 | V5 | 1.80 |
| aVF | 1.65 | V6 | 1.10 |



12SL REPORT

IVY HOSPITAL

YADAV, PINTU

Client ID: 427375

P:03.2024

10:29:53am

Male 180 cm 90 kg

35yrs Indian

120/80 mmHg

PRETEST

SUPINE

00:10


BRUCE

0.0 km/h

0.0 %

| | | |
|--------------|------------|---------------------|
| Vent. Rate | 84 bpm | Normal sinus rhythm |
| PR interval | 144 ms | Normal ECG |
| QRS duration | 88 ms | |
| QT/QTc | 330/389 ms | |
| P-R-T axes | 78/87/69 | |
| P duration | 116 ms | |
| RR interval | 720 ms | |

Technician TANISHA
Medication:



GE
CASE: V6.51 25 mm/s, 10 mm/mV, 60Hz, 0.01 - 20Hz, S+ 12SL 20.1

Start of Test: 10:29:40am

GE Healthcare


EEG 2104768-001

GE MAC1200 ST
SRI LANKA CARDIOPRINT
SRI LANKA HOSPITAL MOHALI

HR 68bpm

Measurement Results:


| | | |
|-----------|---|--------------------|
| QRS | : | 106 ms |
| QT/QTcB | : | 350 / 372 ms |
| PR | : | 138 ms |
| P | : | 98 ms |
| RR/PP | : | 886 / 885 ms |
| P/QRS/T | : | 60/ 70/ 45 degrees |
| QTd/QTcBd | : | 40 / 42 ms |
| Sokolow | : | 1.9 mV |
| NK | : | 8 |



Interpretation:
ST-segment elevation (anterior)
borderline ECG

Pimtu Yadav

Unconfirmed report.





| | | | |
|-------------|------------------|------------------|-----------------------|
| NAME | : MR PINTU YADAV | Requisition Date | : 09/Mar/2024 09:07AM |
| DOB/Gender | : 05-Jan-1989/M | Sample CollDate | : 09/Mar/2024 09:13AM |
| UHID | : 427375 | Sample Rec.Date | : 09/Mar/2024 09:14AM |
| Inv. No. | : 4110113 | Approved Date | : 09/Mar/2024 10:39AM |
| Panel Name | : Ivy Mohali | Referred Doctor | : Self |
| Bar Code No | : 13101070 | | |

| Test Description | Observed Value | Unit | Reference Range |
|------------------|----------------|------|-----------------|
|------------------|----------------|------|-----------------|

IMMUNOASSAY

TOTAL THYROID PROFILE

| | | | |
|--|------|-------|--------------|
| Serum Total T3 <small>(CLIA/Vmax 3000)</small> | 1.31 | ng/mL | 0.970 – 1.69 |
|--|------|-------|--------------|

Summary & Interpretation:

Triiodothyronine (T3) is the hormone principally responsible for the development of the effects of the thyroid hormones on the various target organs. T3 is mainly formed extrathyroidally, particularly in the liver, by deiodination of T4. A reduction in the conversion of T4 to T3 results in a fall in the T3 concentration. It occurs under the influence of medications such as propylthiouracil, glucocorticoids or amiodarone and in severe non-thyroidal illness (NTI). The determination of T3 is utilized in the diagnosis of T3-hyperthyroidism, the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

| | | | |
|--|------|-------|--------------|
| Serum Total T4 <small>(CLIA/Vmax 3000)</small> | 8.08 | µg/dL | 5.52 – 12.97 |
|--|------|-------|--------------|

Summary & Interpretation:

The hormone thyroxine (T4) is the main product secreted by the thyroid gland. The major part of total thyroxine (T4) in serum is present in protein-bound form. As the concentration of the transport proteins in serum are subject to exogenous and endogenous effects, the status of the binding proteins must also be taken into account in the assessment of the thyroid hormone concentration in serum. The determination of T4 can be utilized for the following indications: the detection of hyperthyroidism, the detection of primary and secondary hypothyroidism and the monitoring of TSH-suppression therapy.

| | | | |
|---|-------|-------|----------------|
| Serum TSH <small>(CLIA/Vmax 3000)</small> | 1.000 | mIU/L | 0.4001 – 4.049 |
|---|-------|-------|----------------|

Summary & Interpretation:

TSH is formed in specific basophil cells of the anterior pituitary and is subject to a circadian secretion sequence. The determination of TSH serves as the initial test in thyroid diagnostics. Accordingly, TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid.

Note:

1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4 a.m. and at a minimum between 6-10 pm. The variation is of the order of 50% . hence time of the day has influence on the measured serum TSH concentrations
2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
3. Physiological rise in Total T3/ T4 levels is seen in pregnancy and in patients on steroid therapy.
4. Clinical Use: Primary Hypothyroidism, Hyperthyroidism, Hypothalamic – Pituitary hypothyroidism, Inappropriate TSH secretion, Nonthyroidal illness, Autoimmune thyroid disease, Pregnancy associated thyroid disorders.

| PREGNANCY | REFERENCE RANGE FOR TSH IN uIU/mL |
|---------------|-----------------------------------|
| 1st Trimester | 0.05 – 3.70 |
| 2nd Trimester | 0.31 – 4.35 |
| 3rd Trimester | 0.41 – 5.18 |

The highlighted values should be correlated clinically





NAME : MR PINTU YADAV
 DOB/Gender : 05-Jan-1989/M
 UHID : 427375
 Inv. No. : 4110113
 Panel Name : Ivy Mohali
 Bar Code No : 13101070

Requisition Date : 09/Mar/2024 09:07AM
 Sample CollDate : 09/Mar/2024 09:13AM
 Sample Rec.Date : 09/Mar/2024 09:14AM
 Approved Date : 09/Mar/2024 10:07AM
 Referred Doctor : Self

| Test Description | Observed Value | Unit | Reference Range |
|------------------|----------------|------|-----------------|
|------------------|----------------|------|-----------------|

BIOCHEMISTRY**GLUCOSE FASTING**

Primary Sample Type: Fluoride Plasma

| | | | |
|---|----|-------|---|
| Plasma Glucose Fasting (Hexokinase/ AU480) | 96 | mg/dL | 70 - 99 Normal 100 - 125 Impaired Tolerance ≥126 Diabetic |
|---|----|-------|---|

Interpretation (In accordance with the American diabetes association guidelines):

- A fasting plasma glucose level below 100 mg/dL is considered normal.
- A fasting plasma glucose level between 100-125 mg/dL is considered as glucose intolerant or pre diabetic. A fasting and post-prandial blood sugar test (after consumption of 75 gm of glucose) is recommended for all such patients.
- A fasting plasma glucose level ≥126 mg/dL is highly suggestive of a diabetic state. A repeat fasting test is strongly recommended for all such patients. A fasting plasma glucose level in excess of 126 mg/dL on both the occasions is confirmatory of a diabetic state.

RFT (RENAL FUNCTION TESTS)

| | | | |
|--|-------|-------|-----------|
| Serum Urea (Urease/ GLU/ AU480) | 26.60 | mg/dl | 17-43 |
| Serum Creatinine (JAFTE KINETIC/ AU480) | 0.90 | mg/dl | 0.67-1.17 |
| Serum Uric acid (Urease/ AU480) | 5.30 | mg/dl | 3.5-7.2 |

Interpretation:

Kidney blood tests, or Kidney function tests, are used to detect and diagnose diseases of the Kidney.

The higher the blood levels of urea and creatinine, the less well the kidneys are working.

The level of creatinine is usually used as a marker as to the severity of kidney failure. (Creatinine in itself is not harmful, but a high level indicates that the kidneys are not working properly. So, many other waste products will not be cleared out of the bloodstream.) You normally need treatment with dialysis if the level of creatinine goes higher than a certain value.

Dehydration can also be a cause for increases in urea level.

Before and after starting treatment with certain medicines. Some medicines occasionally cause kidney damage (Nephrotoxic Drug) as a side-effect.

Therefore, kidney function is often checked before and after starting treatment with certain medicines.

Risk associated with renal failure

| | |
|------------------------|----------------------------|
| Acute Renal Failure* | Urea/Creatinine ratio ≥ 20 |
| Chronic Renal Failure* | Urea/Creatinine ratio ≤ 20 |

* Tietz textbook of clinical biochemistry.



The highlighted values should be correlated clinically

Dr. VARUN HATWAL
M.D. PATHOLOGY



NAME : MR PINTU YADAV

DOB/Gender : 05-Jan-1989/M

UHID : 427375

Inv. No. : -4110113

Panel Name : Ivy Mohali

Bar Code No : 13101070

Requisition Date : 09/Mar/2024 09:07AM

Sample CollDate : 09/Mar/2024 09:13AM

Sample Rec.Date : 09/Mar/2024 09:14AM

Approved Date : 09/Mar/2024 10:07AM

Referred Doctor : Self

| Test Description | Observed Value | Unit | Reference Range |
|---|----------------|-------|-----------------|
| LIVER FUNCTION TEST WITH GGT | | | |
| Serum Bilirubin Total <small>(IFP) (AU) (480)</small> | 0.80 | mg/dL | 0.3-1.2 |
| Serum Bilirubin Direct <small>(IFD) (AU) (480)</small> | 0.10 | mg/dl | <0.3 |
| Serum Bilirubin Indirect <small>(Calculated)</small> | 0.70 | mg/dl | 0.1-1.0 |
| Serum SGOT(AST) <small>(IFCC Without PSP) (AU) (480)</small> | 23 | U/L | <35 |
| Serum SGPT(ALT) <small>(IFCC Without PSP) (AU) (480)</small> | 27 | U/L | <50 |
| Serum AST/ALT Ratio <small>(Calculated)</small> | 0.85 | | |
| Serum GGT <small>(IFCC) (AU) (480)</small> | 22 | IU/L | 9-52 |
| Serum Alkaline Phosphatase <small>(IFCC) (PNP/AMPK) (IU/L) (480)</small> | 60 | U/L | 30-120 |
| Serum Protein Total <small>(Biom) (480)</small> | 7.5 | gm/dl | 6.40 - 8.20 |
| Serum Albumin <small>(BCC) (AU) (480)</small> | 4.9 | g/dL | 3.5-5.2 |
| Serum Globulin <small>(Calculated)</small> | 2.60 | gm/dl | 2.0-3.5 |
| Serum Albumin/Globulin Ratio <small>(Calculated)</small> | 1.88 | % | 1.0 - 1.8 |

Interpretation:

Liver blood tests, or liver function tests, are used to detect and diagnose disease or inflammation of the liver. Elevated aminotransferase (ALT, AST) levels are measured as well as alkaline phosphatase, albumin, and bilirubin. Some diseases that cause abnormal levels of ALT and AST include hepatitis A, B, and C, cirrhosis, iron overload, and Tylenol liver damage. Medications also cause elevated liver enzymes. There are less common conditions and diseases that also cause elevated liver enzyme levels.

LIPID PROFILE

| | | | |
|--|-----|-------|--|
| Serum Cholesterol <small>(CHL) (PO) (AU) (480)</small> | 187 | mg/dL | Desirable: <200 Borderline High: 200-239 High: > 240 |
| Serum Triglycerides <small>(Lipase) (PO) (PAP) (AU) (480)</small> | 214 | mg/dL | <150 Normal 150-199 Borderline High 200-499 High >500 Very High |
| Serum HDL Cholesterol | 48 | mg/dL | <40 Major risk factor for CHD |



The highlighted values should be correlated clinically

Dr. VARUN HATWAL
M.D. PATHOLOGY



| | | | |
|-------------|------------------|------------------|-----------------------|
| NAME | : MR PINTU YADAV | | |
| DOB/Gender | : 05-Jan-1989/M | Requisition Date | : 09/Mar/2024 09:07AM |
| UHID | : 427375 | SampleCollDate | : 09/Mar/2024 09:13AM |
| Inv. No. | : 4110113 | Sample Rec.Date | : 09/Mar/2024 09:14AM |
| Panel Name | : Ivy Mohali | Approved Date | : 09/Mar/2024 10:07AM |
| Bar Code No | : 13101070 | Referred Doctor | : Self |

| Test Description | Observed Value | Unit | Reference Range |
|--|----------------|-------|----------------------------------|
| (Hemocozytic=AU400) | | | >60 Negative risk factor for CHD |
| Serum VLDL cholesterol <small>(Calculated)</small> | 43 | mg/dL | 7-35 |
| Serum LDL cholesterol <small>(Calculated)</small> | 96 | mg/dL | 50-100 |
| Serum Cholesterol-HDL Ratio <small>(Calculated)</small> | 3.90 | | 3-5 |
| Serum LDL-HDL Ratio <small>(Calculated)</small> | 2.00 | | 1.5 - 3.5 |

Interpretation:

As per ATP III Guidelines - National Cholesterol Education Program

| | |
|---|--|
| Total Cholesterol (mg/dL) | Desirable <200 Borderline High 200 – 239 High >240 |
| Triglyceride | Normal < 150 Borderline High 150 – 199 High 200 – 499 Very High ≥ 500 |
| HDL – Cholesterol | Low < 40 High ≥ 60 |
| LDL – Cholesterol – Primary Target of Therapy | Optimal < 100 Near optimal/ Above optimal 100 – 129 Borderline high 130 – 159 High 160 – 189 Very high ≥ 190 |

| Risk Category LDL | Goal (mg/dL) | Non-HDL Goal (mg/dL) |
|---|--------------|----------------------|
| CHD and CHD Risk Equivalent <small>10-year risk for CHD>20%</small> | <100 | <130 |
| Multiple (2+) Risk Factors and <small>0-year risk <20%</small> | <130 | <160 |
| ≤1 Risk Factor | <160 | <190 |

e highlighted values should be correlated clinically





IVY HOSPITAL

Sector 71, Mohali, Punjab, 160071

Ph: 9115115257, 9115115258,

9115115624

Email: lab@ivyhospital.com



NAME : MR PINTU YADAV

DOB/Gender : 05-Jan-1989/M

UHID : 427375

Inv. No. : 4110113

Panel Name : Ivy Mohali

Bar Code No : 13101070

Requisition Date : 09/Mar/2024 09:07AM

SampleCollDate : 09/Mar/2024 09:13AM

Sample Rec.Date : 09/Mar/2024 09:14AM

Approved Date : 09/Mar/2024 10:15AM

Referred Doctor : Self

| Test Description | Observed Value | Unit | Reference Range |
|------------------|----------------|------|-----------------|
|------------------|----------------|------|-----------------|

HAEMATOLOGY

ESR

Primary Sample Type: EDTA Blood

| | | | |
|-----|---|------|------|
| ESR | 3 | mm/h | 0-10 |
|-----|---|------|------|

(Automated ESR analysis)



The highlighted values should be correlated clinically





NAME : MR PINTU YADAV
 DOB/Gender : 05-Jan-1989/M
 UHID : 427375
 Inv. No. : 4110113
 Panel Name : Ivy Mohali
 Bar Code No : 13101070

Requisition Date : 09/Mar/2024 09:07AM
 SampleCollDate : 09/Mar/2024 09:13AM
 Sample Rec.Date : 09/Mar/2024 09:14AM
 Approved Date : 09/Mar/2024 10:07AM
 Referred Doctor : Self

| Test Description | Observed Value | Unit | Reference Range |
|------------------|----------------|------|-----------------|
|------------------|----------------|------|-----------------|

HAEMATOLOGY

COMPLETE BLOOD COUNT (Sample Type- Whole Blood EDTA)

| | | | |
|--|------|---------------------|-------------|
| Haemoglobin <small>(Hemoglobin)</small> | 16.4 | g/dl | 13.0 - 17.0 |
| Hematocrit(PCV) <small>(Calculated)</small> | 49.8 | % | 36-48 |
| Red Blood Cell (RBC) <small>(Impedance-DC Detection)</small> | 5.50 | 10 ⁶ /μl | 4.5-5.5 |
| Mean Corp Volume (MCV) <small>(Impedance-DC Detection)</small> | 90.9 | fL | 83-97 |
| Mean Corp HB (MCH) <small>(Calculated)</small> | 29.9 | pg/mL | 27-31 |
| Mean Corp HB Conc (MCHC) <small>(Calculated)</small> | 32.9 | gm/dl | 32-36 |
| Red Cell Distribution Width -CV <small>(Calculated)</small> | 12.5 | % | 11-15 |
| Platelet Count <small>(Impedance-DC Detection/Manual)</small> | 229 | 10 ³ /ul | 150-450 |
| Mean Platelet Volume (MPV) <small>(Impedance-DC Detection)</small> | 10.2 | fL | 7.5-10.3 |
| Total Leucocyte Count (TLC) <small>(Impedance-DC Detection)</small> | 5.8 | 10 ³ /μl | 4.0 - 10.0 |


Differential Leucocyte Count (VCS/ Microscopy)

| | | | |
|---------------------------|-------|----|-----------|
| Neutrophils | 62 | % | 40-75 |
| Lymphocytes | 26 | % | 20-40 |
| Monocytes | 8 | % | 0-8 |
| Eosinophils | 4 | % | 0-4 |
| Basophils | 0 | % | 0-1 |
| Absolute Neutrophil Count | 3,596 | μl | 2000-7000 |
| Absolute Lymphocyte Count | 1,508 | uL | 1000-3000 |
| Absolute Monocyte Count | 464 | uL | 200-1000 |
| Absolute Eosinophil Count | 232 | μl | 20-500 |

*** End Of Report ***

The highlighted values should be correlated clinically





R


0427175 20YU MADAV M 35 years KR 3273 OPD

IN HOSPITAL SECTION MEDICAL



| | | | |
|----------------|-------------|------------------|------------------|
| NAME | PINTU YADAV | SEX/AGE | M35Y |
| PATIENT ID | ID427375 | Accession Number | |
| REF CONSULTANT | PACKAGE | DATE | 09/03/2024 09:29 |

USG WHOLE ABDOMEN



LIVER: is enlarged in size (~18.5 cm), normal in outline and shows increased echogenicity. IHBR are not dilated. Portal vein is normal. Visualized CBD is not dilated.

GALL BLADDER: is normally distended. GB wall is normal. No echoes are seen in GB.

SPLEEN: is borderline enlarged in size (~12.4 cm), normal in outline and echotexture.

PANCREAS & UPPER RETROPERITONEUM: Visualised pancreatic head and proximal body are normal in size and echotexture. Tail of pancreas is obscured by bowel gas.

RIGHT KIDNEY: It is normal in size (~11.7 cm), outline and echotexture. Corticomedullary differentiation is well-defined. No hydronephrosis is seen.

LEFT KIDNEY: It is normal in size (~11.4 cm), outline and echotexture. Corticomedullary differentiation is well-defined. No hydronephrosis is seen.

U-BLADDER: is minimally distended at the time of examination.

PROSTATE: is normal in size.

No free fluid is seen in peritoneal cavity.

IMPRESSION:

Hepatomegaly with fatty liver (Grade I/II).

Borderline splenomegaly.

Adv. Clinical correlation and follow up

Dr. Shruti

(NOT FOR MEDICO-LEGAL PURPOSE)



Ivy Hospital

SUPER-SPECIALITY HEALTHCARE
SECTOR 71, MOHALI
Tel: 0172-7170000
CIN No. : U85110PB2005PTC027898

| | | | |
|----------------|-------------|------------------|------------------|
| NAME | PINTU YADAV | SEX/AGE | M35Y |
| PATIENT ID | ID427375 | Accession Number | |
| REF CONSULTANT | PACKAGE | DATE | 09/03/2024 09:29 |

DNB Resident



DR EKTA MISHRA
MD RADIO-DIAGNOSIS

The above impression is just an opinion of the imaging findings and not a final diagnosis. Needs correlation with clinical status, lab investigations and other relevant investigations

(NOT FOR MEDICO-LEGAL PURPOSE)